Pharma relying on external innovation, report shows
LONDON – Pharma’s dependence on biotechs and academics for innovation is highlighted in an analysis of the 94 novel drugs approved in Europe from 2010 to 2012, which shows that while 87 percent of the approvals were granted to pharmaceutical companies, more than half of the products had their origins outside corporate laboratories.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter